國立虎尾科技大學 |

HCV: The Journey from Discovery to a Cure = Volume II /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	HCV: The Journey from Discovery to a Cure/ edited by Michael J. Sofia.
其他題名:	Volume II /
其他作者:	Sofia, Michael J.
面頁冊數:	VIII, 500 p. 50 illus., 20 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Medicinal chemistry. -
電子資源:	https://doi.org/10.1007/978-3-030-28400-8
ISBN:	9783030284008

HCV: The Journey from Discovery to a Cure = Volume II /
HCV: The Journey from Discovery to a CureVolume II /[electronic resource] :edited by Michael J. Sofia. - 1st ed. 2019. - VIII, 500 p. 50 illus., 20 illus. in color.online resource. - Topics in Medicinal Chemistry,321862-2461 ;. - Topics in Medicinal Chemistry,15.

NS5A as a target for HCV Drug Discovery -- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex -- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni® -- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa® and Vosevi® -- Discovery of Elbasvir -- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments -- Evolution of HCV NS4B Inhibitors -- The Evolution of Clinical Trials for Hepatitis C -- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®) -- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®) -- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®) -- Clinical Development of Viekira Pak to Mavyret -- Development of ZEPATIER® -- Real world effectiveness of DAA therapies -- The Benefit of Direct-Acting Antiviral HCV Cure Therapies -- Cure and Control: What Will It Take to Eliminate HCV? -- Perspectives on HCV Cure.

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".

ISBN: 9783030284008

Standard No.: 10.1007/978-3-030-28400-8doiSubjects--Topical Terms:

1253747
Medicinal chemistry.

LC Class. No.: RS400-431

Dewey Class. No.: 615.19

HCV: The Journey from Discovery to a Cure = Volume II /
LDR:03971nam a22004095i 4500 001 1009479
003 DE-He213
005 20200703003736.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030284008 $9 978-3-030-28400-8
024 7 $a 10.1007/978-3-030-28400-8 $2 doi
035 $a 978-3-030-28400-8
050 4 $a RS400-431
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a HCV: The Journey from Discovery to a Cure $h [electronic resource] : $b Volume II / $c edited by Michael J. Sofia.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a VIII, 500 p. 50 illus., 20 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Topics in Medicinal Chemistry, $x 1862-2461 ; $v 32
505 0 $a NS5A as a target for HCV Drug Discovery -- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex -- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni® -- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa® and Vosevi® -- Discovery of Elbasvir -- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments -- Evolution of HCV NS4B Inhibitors -- The Evolution of Clinical Trials for Hepatitis C -- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®) -- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®) -- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®) -- Clinical Development of Viekira Pak to Mavyret -- Development of ZEPATIER® -- Real world effectiveness of DAA therapies -- The Benefit of Direct-Acting Antiviral HCV Cure Therapies -- Cure and Control: What Will It Take to Eliminate HCV? -- Perspectives on HCV Cure.
520 $a Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".
650 0 $a Medicinal chemistry. $3 1253747
650 0 $a Virology. $3 644995
650 0 $a Medical biochemistry. $3 1254555
650 0 $a Bioorganic chemistry. $3 743635
650 0 $a Pharmaceutical technology. $3 557391
650 1 4 $a Medicinal Chemistry. $3 668872
650 2 4 $a Medical Biochemistry. $3 668897
650 2 4 $a Bioorganic Chemistry. $3 677511
650 2 4 $a Pharmaceutical Sciences/Technology. $3 768561
700 1 $a Sofia, Michael J. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1303413
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030283995
776 0 8 $i Printed edition: $z 9783030284015
776 0 8 $i Printed edition: $z 9783030284022
830 0 $a Topics in Medicinal Chemistry, $x 1862-2461 ; $v 15 $3 1253746
856 4 0 $u https://doi.org/10.1007/978-3-030-28400-8
912 $a ZDB-2-CMS
912 $a ZDB-2-SXC
950 $a Chemistry and Materials Science (SpringerNature-11644)
950 $a Chemistry and Material Science (R0) (SpringerNature-43709)